These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 27465794)
1. Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Lv W; Guan L; Zhang Y; Yu S; Cao B; Ji Y Int Urol Nephrol; 2016 Dec; 48(12):2043-2050. PubMed ID: 27465794 [TBL] [Abstract][Full Text] [Related]
11. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Viaene L; Behets GJ; Claes K; Meijers B; Blocki F; Brandenburg V; Evenepoel P; D'Haese PC Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174 [TBL] [Abstract][Full Text] [Related]
12. The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis. Paccou J; Mentaverri R; Renard C; Liabeuf S; Fardellone P; Massy ZA; Brazier M; Kamel S J Clin Endocrinol Metab; 2014 Dec; 99(12):4740-8. PubMed ID: 25222755 [TBL] [Abstract][Full Text] [Related]
13. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Brandenburg VM; Verhulst A; Babler A; D'Haese PC; Evenepoel P; Kaesler N Nephrol Dial Transplant; 2019 Mar; 34(3):408-414. PubMed ID: 29846712 [TBL] [Abstract][Full Text] [Related]
14. Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease. Ji YQ; Guan LN; Yu SX; Yin PY; Shen XQ; Sun ZW; Liu J; Lv W; Yu GP; Ren C Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8822-8829. PubMed ID: 30575924 [TBL] [Abstract][Full Text] [Related]
15. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Figurek A; Spasovski G Int Urol Nephrol; 2018 Oct; 50(10):1863-1870. PubMed ID: 30030677 [TBL] [Abstract][Full Text] [Related]
16. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease]. Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189 [TBL] [Abstract][Full Text] [Related]
17. Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Li M; Zhou H; Yang M; Xing C Int Urol Nephrol; 2019 Feb; 51(2):311-323. PubMed ID: 30515734 [TBL] [Abstract][Full Text] [Related]
18. High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients. Jean G; Chazot C; Bresson E; Zaoui E; Cavalier E Nephron; 2016; 132(3):181-90. PubMed ID: 26890570 [TBL] [Abstract][Full Text] [Related]
19. Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. Zhou H; Yang M; Li M; Cui L Int Urol Nephrol; 2017 Aug; 49(8):1433-1437. PubMed ID: 28455660 [TBL] [Abstract][Full Text] [Related]
20. Sclerostin levels in uremic patients: a link between bone and vascular disease. Bruzzese A; Lacquaniti A; Cernaro V; Ricciardi CA; Loddo S; Romeo A; Montalto G; Costantino G; Torre F; Pettinato G; Salamone I; Aloisi C; Santoro D; Buemi M Ren Fail; 2016 Jun; 38(5):759-64. PubMed ID: 27001371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]